Azad Raj Vardhan, Khan Mansur Ali, Chanana Bhuvan, Azad Shorya
Vitreo-Retina Services, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
Jpn J Ophthalmol. 2008 Jan-Feb;52(1):52-6. doi: 10.1007/s10384-007-0496-4. Epub 2008 Mar 28.
To investigate the 6-month safety profile and clinical outcomes of intravitreal bevacizumab for treating subfoveal choroidal neovascularization (CNV) in age-related macular degeneration (AMD).
We performed a prospective nonrandomized interventional study of 40 consecutive patients (40 eyes) with subfoveal CNV due to AMD. Patients underwent standard ophthalmic examination, optical coherence tomography, and fundus fluorescein angiography. All patients were administered one or more intravitreal injections of bevacizumab (1.25 mg) as primary therapy. Outcomes were also analyzed in subgroups based on lesion type (classic or occult) and lesion size (< or =3000 microm or >3000 microm).
At the 6 months' follow-up, mean best-corrected visual acuity (BCVA) improved from 20/160 to 20/100 (P = 0.014), and the mean contrast sensitivity improved from 0.38 to 0.62 (P = 0.001). The mean greatest linear diameter and mean central macular thickness significantly decreased from 3.79 mm to 2.4 mm (P = 0.0001) and from 438.5 microm to 363 microm (P = 0.0001), respectively. Visual acuity gain of 15 letters or more was seen in 20% of patients, and the gain was more in the small-lesion subgroup (31.5%) than in the large-lesion subgroup (9.5%). No significant adverse effects were observed.
Intravitreal bevacizumab is a safe and effective modality for treatment of CNV secondary to AMD. A significant improvement in BCVA with intravitreal bevacizumab was observed for all lesion types.
研究玻璃体内注射贝伐单抗治疗年龄相关性黄斑变性（AMD）所致黄斑中心凹下脉络膜新生血管（CNV）的6个月安全性及临床疗效。
我们对40例连续的因AMD导致黄斑中心凹下CNV的患者（40只眼）进行了一项前瞻性非随机干预性研究。患者接受了标准眼科检查、光学相干断层扫描及眼底荧光血管造影。所有患者均接受一次或多次玻璃体内注射贝伐单抗（1.25mg）作为主要治疗。还根据病变类型（典型或隐匿性）及病变大小（≤3000微米或＞3000微米）对亚组的结果进行了分析。
在6个月的随访中，平均最佳矫正视力（BCVA）从20/160提高到20/100（P = 0.014），平均对比敏感度从0.38提高到0.62（P = 0.001）。平均最大直线直径和平均黄斑中心厚度分别从3.79mm显著降至2.4mm（P = 0.0001）和从438.5微米降至363微米（P = 0.0001）。20%的患者视力提高了15行或更多，小病变亚组（31.5%）的提高幅度大于大病变亚组（9.5%）。未观察到明显不良反应。
玻璃体内注射贝伐单抗是治疗AMD继发CNV的一种安全有效的方法。观察到玻璃体内注射贝伐单抗对所有病变类型的BCVA均有显著改善。
